Uncovering the dynamic effects of DEX treatment on lung cancer by integrating bioinformatic inference and multiscale modeling of scRNA-seq and proteomics data

dc.contributor.authorChen, Minghan
dc.contributor.authorXu, Chunrui
dc.contributor.authorXu, Ziang
dc.contributor.authorHe, Wei
dc.contributor.authorZhang, Haorui
dc.contributor.authorSu, Jing
dc.contributor.authorSong, Qianqian
dc.contributor.departmentBiostatistics, School of Public Health
dc.date.accessioned2023-10-09T13:33:08Z
dc.date.available2023-10-09T13:33:08Z
dc.date.issued2022
dc.description.abstractLung cancer is one of the leading causes of cancer-related death, with a five-year survival rate of 18%. It is a priority for us to understand the underlying mechanisms affecting lung cancer therapeutics’ implementation and effectiveness. In this study, we combine the power of Bioinformatics and Systems Biology to comprehensively uncover functional and signaling pathways of drug treatment using bioinformatics inference and multiscale modeling of both scRNA-seq data and proteomics data. Based on a time series of lung adenocarcinoma derived A549 cells after DEX treatment, we first identified the differentially expressed genes (DEGs) in those lung cancer cells. Through the interrogation of regulatory network of those DEGs, we identified key hub genes including TGFβ, MYC, and SMAD3 varied underlie DEX treatment. Further gene set enrichment analysis revealed the TGFβ signaling pathway as the top enriched term. Those genes involved in the TGFβ pathway and their crosstalk with the ERBB pathway presented a strong survival prognosis in clinical lung cancer samples. With the basis of biological validation and literature-based curation, a multiscale model of tumor regulation centered on both TGFβ-induced and ERBB-amplified signaling pathways was developed to characterize the dynamic effects of DEX therapy on lung cancer cells. Our simulation results were well matched to available data of SMAD2, FOXO3, TGFβ1, and TGFβR1 over the time course. Moreover, we provided predictions of different doses to illustrate the trend and therapeutic potential of DEX treatment. The innovative and cross-disciplinary approach can be further applied to other computational studies in tumorigenesis and oncotherapy. We released the approach as a user-friendly tool named BIMM (Bioinformatic Inference and Multiscale Modeling), with all the key features available at https://github.com/chenm19/BIMM.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationChen M, Xu C, Xu Z, et al. Uncovering the dynamic effects of DEX treatment on lung cancer by integrating bioinformatic inference and multiscale modeling of scRNA-seq and proteomics data. Comput Biol Med. 2022;149:105999. doi:10.1016/j.compbiomed.2022.105999
dc.identifier.urihttps://hdl.handle.net/1805/36222
dc.language.isoen_US
dc.publisherElsevier
dc.relation.isversionof10.1016/j.compbiomed.2022.105999
dc.relation.journalComputers in Biology and Medicine
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectSingle-cell RNA-seq
dc.subjectMulti-modal omics data
dc.subjectBioinformatics inference
dc.subjectMultiscale modeling
dc.titleUncovering the dynamic effects of DEX treatment on lung cancer by integrating bioinformatic inference and multiscale modeling of scRNA-seq and proteomics data
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms-1840381.pdf
Size:
1.44 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: